Literature DB >> 28051257

Downregulation of miR-361-5p associates with aggressive clinicopathological features and unfavorable prognosis in non-small cell lung cancer.

Z-L Zhuang1, F-M Tian, C-L Sun.   

Abstract

OBJECTIVE: To assess the impact of miR-361-5p expression levels on non-small-cell lung cancer (NSCLC) survival. PATIENTS AND METHODS: A total of 183 patients with NSCLC who underwent surgery between October 2007 and April 2010 were included in this study. Expression levels of miR-361-5p were detected by using qRT-PCR. The association of miR-361-5p expression with clinicopathologic characteristics of NSCLC patients was analyzed. Kaplan-Meier Plotter was performed to identify the prognostic roles of miR-361-5p in NSCLC patients. Finally, multivariate analysis was performed using the Cox proportional hazard analysis.
RESULTS: Results indicated that miR-361-5p was lowly expressed in NSCLC compared with adjacent non-malignant tissues (p < 0.01). And low miR-361-5p expression in NSCLC was significantly correlated with TNM stage (p = 0.000), lymph node metastasis (p = 0.001) and lymphatic invasion (p = 0.032). Kaplan-Meier analysis with the log-rank test indicated that low miR-361-5p expression had a significant impact on overall survival (p < 0.001). Furthermore, Multivariate analyses indicated that miR-361-5p represented an independent predictor for overall survival of NSCLC (p = 0.007).
CONCLUSIONS: Our work revealed that miR-361-5p played critical roles in NSCLC progression and could represent a novel prognostic marker in NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28051257

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway.

Authors:  Lei Tian; Zhifeng Zhao; Ling Xie; JinPeng Zhu
Journal:  Oncotarget       Date:  2017-12-20

Review 2.  MicroRNA-361: A Multifaceted Player Regulating Tumor Aggressiveness and Tumor Microenvironment Formation.

Authors:  Daozhi Xu; Peixin Dong; Ying Xiong; Junming Yue; Kei Ihira; Yosuke Konno; Noriko Kobayashi; Yukiharu Todo; Hidemichi Watari
Journal:  Cancers (Basel)       Date:  2019-08-07       Impact factor: 6.639

3.  Dysregulation of serum miR-361-5p serves as a biomarker to predict disease onset and short-term prognosis in acute coronary syndrome patients.

Authors:  Wenqing Zhang; Guannan Chang; Liya Cao; Gang Ding
Journal:  BMC Cardiovasc Disord       Date:  2021-02-05       Impact factor: 2.298

Review 4.  MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.

Authors:  Javaid Ahmad Wani; Sabhiya Majid; Zuha Imtiyaz; Muneeb U Rehman; Rana M Alsaffar; Naveed Nazir Shah; Sultan Alshehri; Mohammed M Ghoneim; Syed Sarim Imam
Journal:  Diagnostics (Basel)       Date:  2022-07-01

5.  Serum Extracellular Vesicle-Derived miRNAs in Patients with Non-Small Cell Lung Cancer-Search for Non-Invasive Diagnostic Biomarkers.

Authors:  Jolanta Kryczka; Monika Migdalska-Sęk; Jacek Kordiak; Justyna M Kiszałkiewicz; Dorota Pastuszak-Lewandoska; Adam Antczak; Ewa Brzeziańska-Lasota
Journal:  Diagnostics (Basel)       Date:  2021-03-03

6.  MicroRNA-361-5p slows down gliomas development through regulating UBR5 to elevate ATMIN protein expression.

Authors:  Mingming Zhang; Mengqiang Yu; Jiaoying Jia; Zhu Ouyang; Ming Wang; Wenjia Ma; Min Liu
Journal:  Cell Death Dis       Date:  2021-07-28       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.